Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
Sponsor: Corxel Pharmaceuticals
Summary
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
Official title: A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities
Key Details
Gender
FEMALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-05-11
Completion Date
2027-06
Last Updated
2026-06-16
Healthy Volunteers
No
Conditions
Interventions
CX11
CX11 tablets administered orally once daily (QD) with meals
Placebo
Matching placebo tablets administered orally once daily (QD) with meals
CX11
CX11 tablets administered orally once daily (QD) with high fat, high calorie meal
Locations (2)
Corxel Investigational site
Las Vegas, Nevada, United States
Corxel Investigational Site
Austin, Texas, United States